Headache and Migraine

As part of NeurologyLive®'s Year in Review, we've compiled the most-read question-and-answer interviews we've conducted with experts in various neurology specialties in 2022.

The director of the Headache Center at Allegheny Health Network provided perspective on the process of identifying a patient with chronic migraine and initiating a proper treatment plan. [WATCH TIME: 7 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 16, 2022.

The director of the Headache Center at Allegheny Health Network provided perspective on whether focusing in on medications or lifestyle choices has better impacts on improving chronic migraine. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and related dementias.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 9, 2022.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.

Neurology News Network for the week ending December 3, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 2, 2022.

In a post-hoc analysis of the ADVANCE trial, atogepant 30 and 60 mg produced significant improvements in outcomes on Migraine-Specific Quality of Life Questionnaire and Activity Impairment in Migraine-Diary domains.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 25, 2022.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Neurology News Network for the week ending November 19, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 18, 2022.

Six months after hospital discharge, COVD-19 headache was more frequently observed in those infected with the Delta variant vs Wuhan or Alpha variants.

The newly announced prospective, randomized, placebo- and sham-controlled study, will include 150 patients, ages 18 to 55 years, with documented patent foramen ovale and a history of more than 1 migraine headache day per week.

Evidence of therapeutic benefit for zavegepant was observed on multiple secondary end points, including return to normal function at 30 min postdose, sustained pain relief, and sustained pain freedom.

Here's some of what is coming soon to NeurologyLive® this week.